Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E14.93 EPS (ttm)12.53 Insider Own0.20% Shs Outstand622.00M Perf Week6.26%
Market Cap116.38B Forward P/E12.70 EPS next Y14.73 Insider Trans-0.80% Shs Float608.63M Perf Month9.23%
Income8.08B PEG7.59 EPS next Q3.59 Inst Own80.30% Short Float1.66% Perf Quarter0.22%
Sales23.75B P/S4.90 EPS this Y14.80% Inst Trans-2.88% Short Ratio3.55 Perf Half Y0.87%
Book/sh17.41 P/B10.75 EPS next Y5.25% ROA12.20% Target Price205.55 Perf Year0.32%
Cash/sh42.28 P/C4.43 EPS next 5Y1.97% ROE61.40% 52W Range166.30 - 210.19 Perf YTD-3.88%
Dividend5.80 P/FCF18.60 EPS past 5Y13.70% ROI19.80% 52W High-11.86% Beta1.15
Dividend %3.10% Quick Ratio2.50 Sales past 5Y4.90% Gross Margin82.30% 52W Low11.40% ATR3.11
Employees21500 Current Ratio2.80 Sales Q/Q0.10% Oper. Margin42.10% RSI (14)68.54 Volatility1.86% 1.73%
OptionableYes Debt/Eq3.05 EPS Q/Q-2.10% Profit Margin34.00% Rel Volume0.59 Prev Close187.11
ShortableYes LT Debt/Eq2.71 EarningsJul 30 AMC Payout42.90% Avg Volume2.86M Price185.26
Recom2.20 SMA205.59% SMA505.10% SMA200-2.36% Volume1,537,469 Change-0.99%
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Outperform $208
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-24-19 10:27AM  Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids Zacks
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-21-19 09:15AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Jun-20-19 05:50PM  Amgen (AMGN) Gains But Lags Market: What You Should Know Zacks
09:45AM  The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara Zacks
Jun-19-19 04:00PM  Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership PR Newswire
11:49AM  3 Large-Cap Biotech Stocks to Buy for Massive Gains InvestorPlace
11:04AM  The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands Zacks
10:29AM  Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data Zacks
10:21AM  Merck's Keytruda Gets 2nd Label Expansion Approval in June Zacks
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
Jun-18-19 01:00PM  Top Analyst Reports for Broadcom, Amgen & NVIDIA Zacks
08:03AM  Roche's Rozlytrek Gets Approval in Japan for Solid Tumors Zacks
08:00AM  Looking For Great Stocks? First Use A Checklist To Identify Great Bases Investor's Business Daily
08:00AM  3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal Motley Fool
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-16-19 02:00AM  Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 PR Newswire
Jun-14-19 05:48PM  UPDATE 1-U.S. drugmakers file lawsuit against requiring drug prices in TV ads Reuters
03:14PM  U.S. drugmakers file lawsuit against rule requiring drug prices in TV ads Reuters
08:47AM  The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga
08:34AM  Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti Zacks
05:19AM  Drugmakers sue to stop rule requiring prices in TV ads Financial Times
Jun-13-19 07:13PM  FDA Approves Amgen And Allergan's KANJINTI (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) PR Newswire
05:40PM  Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris Zacks
04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
09:36AM  Ligand Inks Oncology Drug Discovery Deal With PhoreMost Zacks
09:31AM  Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks
Jun-12-19 06:33PM  Roche's Rituxan Gets Priority Review for Blood Disorder Zacks
05:50PM  Amgen (AMGN) Gains As Market Dips: What You Should Know Zacks
09:00AM  Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution PR Newswire
08:33AM  Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer Zacks
Jun-11-19 09:54AM  Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II Zacks
Jun-10-19 09:39AM  Roche Receives FTC Request for Further Data on Spark Buyout Zacks
Jun-07-19 04:00PM  Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
09:59AM  Mirati Therapeutics Stock Will Fall From Here, Analyst Says
Jun-06-19 05:59PM  Is Amgen, Inc. (AMGN) A Good Stock To Buy? Insider Monkey
05:50PM  Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know Zacks
03:13PM  5 Healthcare Stocks to Pick Up From the Wreckage InvestorPlace
02:30PM  Should We Be Delighted With Amgen Inc.'s (NASDAQ:AMGN) ROE Of 75%? Simply Wall St.
09:22AM  Lilly's Emgality Gets FDA Approval for Cluster Headache Zacks
09:09AM  Was ASCO Quieter for Big Drug/Biotech Stocks This Year? Zacks
Jun-05-19 01:07PM  Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients
09:05AM  Pfizer to Launch Several Drugs Despite Generic Headwinds Zacks
08:00AM  Iovance and Amgen Are Making Cancer History Bloomberg
07:32AM  Amgen's early-stage study of cancer treatment had 'adverse events' in nearly half of its patients MarketWatch
07:00AM  Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019 CNW Group
07:00AM  Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019 CNW Group
Jun-04-19 06:45PM  Amgen Drug Breaks New Ground
05:06PM  FDA approves Lilly's migraine drug as first ever cluster headache treatment Reuters
12:37PM  Amgens Good News on Lung Cancer Boosted Mirati Therapeutics. Heres What Wall Street Is Saying.
11:50AM  Sanofi loses German patent case against Amgen over cholesterol drug Reuters
10:53AM  How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's? Benzinga
10:19AM  Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks
09:30AM  Company News For Jun 4, 2019 Zacks
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 05:04PM  US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag Reuters
04:30PM  Amgen and PHV rise while Alphabet and Centene slip Associated Press
04:24PM  Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein? Investor's Business Daily
03:25PM  US STOCKS-Wall Street falls as Facebook, Alphabet, Amazon drag Reuters
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
01:40PM  US STOCKS-Wall Street tumbles as Facebook, Alphabet extend slide Reuters
12:47PM  Amgen Stock Jumps on Promising Cancer Drug Trial Results
12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
11:35AM  Amgen Shares Gain on Positive Lung-Cancer Trial Results
11:17AM  US STOCKS-Wall St edges higher, boosted by healthcare; Alphabet, Amazon pressure Nasdaq Reuters
11:11AM  Amgen drug shows high response rate in small lung and colon cancer trial Reuters
09:28AM  Amgen drug shows high response rate in small lung and colon cancer trial Reuters
09:01AM  Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend
09:00AM  Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019 PR Newswire
05:32AM  Amgen Rises 3%
Jun-02-19 09:00PM  Amgen drug takes aim at cancer master switch Financial Times
10:45AM  Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019 PR Newswire
Jun-01-19 11:37AM  The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga
May-31-19 05:45PM  Amgen (AMGN) Dips More Than Broader Markets: What You Should Know Zacks
01:04PM  What to watch at the world's largest cancer conference CNBC Videos
12:32PM  What to expect from the ASCO annual conference Yahoo Finance Video
May-30-19 03:11PM  Ranking the Top 10 Stock Buybacks of Last Year InvestorPlace
09:31AM  Amgen (AMGN) Down 4% Since Last Earnings Report: Can It Rebound? Zacks
08:28AM  Amarin Rises on Priority Review for Vascepa Label Expansion Zacks
May-29-19 04:00PM  Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO) PR Newswire
03:29PM  Merck (MRK) Up This Year So Far: Will the Momentum Continue? Zacks
10:22AM  Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion Zacks
02:00AM  Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution PR Newswire
May-28-19 04:00PM  Amgen Joins With Community Oncology Networks For New Research Collaboration PR Newswire
11:30AM  British Columbia to be first Canadian province to switch patients to biosimilars Reuters
May-27-19 05:24PM  Canada's BC will be first province to switch patients to biosimilars Reuters
01:24AM  3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million American City Business Journals
May-26-19 09:00AM  3 Charts Every Amgen Investor Needs to See Motley Fool
May-24-19 01:16PM  Final Trades: Amgen, Costco, The Communications Sector & Defense stocks CNBC Videos
May-23-19 12:47PM  Buy Amgen and Gilead Stock as Biotech Returns to Stability and Growth
10:38AM  Amgen (AMGN) Offers to Acquire Drug Discovery Platform Zacks
May-22-19 10:14AM  Amgen To Buy Danish Collaborator Nuevolution For $167M Benzinga
03:23AM  Amgen offers to buy Copenhagen-based Nuevolution for $167 mln Reuters
02:00AM  Amgen announces a recommended public cash offer to the shareholders of Nuevolution PR Newswire
May-21-19 04:00PM  Amgen Announces Voting Results Of Annual Meeting Of Stockholders PR Newswire
03:00PM  Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending Insider Monkey
May-20-19 09:42AM  Medicines Company Rallies On Positive LDL Cholesterol Study Results Benzinga
09:04AM  Ligand Grants Preclinical Candidate Rights to UK-based Firm Zacks
May-17-19 12:29PM  Who Had the Better Quarter: Gilead Sciences or Amgen? Motley Fool
07:33AM  Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorJun 05Option Exercise54.712,000109,42016,219Jun 05 06:55 PM
SUGAR RONALD DDirectorJun 05Sale175.682,000351,36014,219Jun 05 06:55 PM
SUGAR RONALD DDirectorMay 01Option Exercise54.712,000109,42015,092May 03 05:37 PM
SUGAR RONALD DDirectorMay 01Sale175.732,000351,46013,092May 03 05:37 PM
SUGAR RONALD DDirectorApr 03Option Exercise54.712,000109,42015,092Apr 03 06:27 PM
SUGAR RONALD DDirectorApr 03Sale193.182,000386,36013,092Apr 03 06:27 PM
SUGAR RONALD DDirectorMar 06Option Exercise54.712,000109,42014,988Mar 08 07:47 PM
SUGAR RONALD DDirectorMar 06Sale188.882,000377,76012,988Mar 08 07:47 PM
SUGAR RONALD DDirectorFeb 07Option Exercise54.712,000109,42014,988Feb 11 09:27 PM
SUGAR RONALD DDirectorFeb 07Sale190.002,000380,00012,988Feb 11 09:27 PM
Jacks TylerDirectorDec 06Option Exercise82.6020,0001,652,00028,979Dec 10 08:46 PM
Jacks TylerDirectorDec 06Sale195.4120,0003,908,2328,979Dec 10 08:46 PM
Piacquad DavidSVP, Business DevelopmentNov 30Option Exercise54.696,500355,48545,128Dec 03 08:13 PM
Patton Cynthia MSVP & CCONov 29Option Exercise54.691,77797,18423,090Dec 03 08:11 PM
Patton Cynthia MSVP & CCONov 29Sale202.881,777360,52021,313Dec 03 08:11 PM
HENDERSON REBECCA MDirectorAug 10Option Exercise63.113,000189,33016,197Aug 14 08:29 PM
Harper Sean EEVP, Research & DevelopmentJul 16Sale195.711,525298,45856,082Jul 16 08:20 PM